Advances in respiratory virus therapeutics – A meeting report from the 6th isirv Antiviral Group conference

Antiviral Research

Volumn 167, Issue , 2019, Pages 45-67

  Beigel, John H ^a   Nam, Hannah H ^b   Adams, Peter L ^c   Krafft, Amy ^a   Ince, William L ^d   El Kamary, Samer S ^d   Sims, Amy C ^e  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e IL   (United States)

Author keywords

Antiviral therapy; Coronavirus; Host directed therapeutics; Influenza; Respiratory syncytial virus

Indexed keywords

1,4 DIHYDRO 2,4,6 TRIMETHYL 3,5 PYRIDINEDICARBOXYLIC ACID METHYL 2 PHENYLTHIOETHYL ESTER; AK 0529; ANTIVIRUS AGENT; ARBIDOL; BALOXAVIR; BALOXAVIR MARBOXIL; CC 42344; DF 2162; DILTIAZEM; DOXYCYCLINE; EDP 938; EIDD 1931; EIDD 2801; ERITORAN; FAVIPIRAVIR; GEDIVUMAB; IMMUNOGLOBULIN; INFLUENZA VIRUS HEMAGGLUTININ; JNJ 53718678; LUMICITABINE; MONOCLONAL ANTIBODY; NITAZOXANIDE; OSELTAMIVIR; PEPTIDE CONJUGATE VACCINE; PIMODIVIR; PRESATOVIR; PROTEIN M2 1; REMDESIVIR; SIALIDASE INHIBITOR; UMIFENOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VH 244; VIS 410; ZIRESOVIR; ADENOSINE PHOSPHATE; ALANINE;

ANTIBODY TITER; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ARTIFICIAL VENTILATION; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; CELL METABOLISM; CELL MIGRATION; CLINICAL OUTCOME; CLINICAL PHARMACOLOGY; CLINICAL TRIAL (TOPIC); CORONAVIRINAE; DRUG ABSORPTION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG REPOSITIONING; DRUG SCREENING; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; HEALTH PROGRAM; HOSPITAL PATIENT; HOST CELL; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; HUMAN RHINOVIRUS; IC50; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; INFLUENZA; INFLUENZA A; INFLUENZA B; INFLUENZA B VIRUS; LEUKOCYTE ACTIVATION; LOWER RESPIRATORY TRACT INFECTION; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MORTALITY; NONHUMAN; NUCLEAR EXPORT; OUTCOME ASSESSMENT; PANDEMIC INFLUENZA; PATIENT-REPORTED OUTCOME; PHARMACODYNAMICS; PRECLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY VIRUS; REVIEW; RNA SPLICING; SARS CORONAVIRUS; SEASONAL INFLUENZA; SECONDARY INFECTION; SURVIVAL; THERAPEUTIC INDEX; TREATMENT RESPONSE; TROUGH CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; VIRAL RESPIRATORY TRACT INFECTION; VIRUS GENOME; VIRUS LOAD; VIRUS REPLICATION; CORONAVIRUS INFECTION; GENETICS; PANDEMIC; PATHOGENICITY; RESPIRATORY TRACT INFECTION; VIROLOGY;

ADENOSINE MONOPHOSPHATE; ALANINE; ANTIVIRAL AGENTS; CORONAVIRUS INFECTIONS; HUMANS; INFLUENZA, HUMAN; PANDEMICS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RESPIRATORY TRACT INFECTIONS;

EID: 85064122575     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2019.04.006     Document Type: Review

References (145)

1. Agostini, M.L., Andres, E.L., Sims, A.C., Graham, R.L., Sheahan, T.P., Lu, X., Smith, E.C., Case, J.B., Feng, J.Y., Jordan, R., Ray, A.S., Cihlar, T., Siegel, D., Mackman, R.L., Clarke, M.O., Baric, R.S., Denison, M.R., Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio, 9, 2018.
2. Al Ghamdi, M., Alghamdi, K.M., Ghandoora, Y., Alzahrani, A., Salah, F., Alsulami, A., Bawayan, M.F., Vaidya, D., Perl, T.M., Sood, G., Treatment outcomes for patients with middle eastern respiratory syndrome coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia. BMC Infect. Dis., 16, 2016, 174.
3. Al-Tawfiq, J.A., Momattin, H., Dib, J., Memish, Z.A., Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int. J. Infect. Dis. 20 (2014), 42–46.
4. Anderson, L.J., Parker, R.A., Strikas, R.L., Association between respiratory syncytial virus outbreaks and lower respiratory tract deaths of infants and young children. J. Infect. Dis. 161 (1990), 640–646.
5. Anthony, S.J., Gilardi, K., Menachery, V.D., Goldstein, T., Ssebide, B., Mbabazi, R., Navarrete-Macias, I., Liang, E., Wells, H., Hicks, A., Petrosov, A., Byarugaba, D.K., Debbink, K., Dinnon, K.H., Scobey, T., Randell, S.H., Yount, B.L., Cranfield, M., Johnson, C.K., Baric, R.S., Lipkin, W.I., Mazet, J.A., Further evidence for bats as the evolutionary source of Middle East respiratory syndrome coronavirus. mBio, 8, 2017.
6. Arabi, Y., Balkhy, H., Hajeer, A.H., Bouchama, A., Hayden, F.G., Al-Omari, A., Al-Hameed, F.M., Taha, Y., Shindo, N., Whitehead, J., Merson, L., AlJohani, S., Al-Khairy, K., Carson, G., Luke, T.C., Hensley, L., Al-Dawood, A., Al-Qahtani, S., Modjarrad, K., Sadat, M., Rohde, G., Leport, C., Fowler, R., Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. SpringerPlus, 4, 2015, 709.
7. Arabi, Y.M., Shalhoub, S., Omari, A.A., Mandourah, Y., Al-Hameed, F., Sindi, A., Alraddadi, B., Motairi, A.A., Khatib, K.A., Mommin, A.A., Qushmaq, I.A., Mady, A., Solaiman, O., Aithan, A.A., Balkhy, H.H., Al-Raddadi, R., Rajab, A., Mekhlafi, G.A.A., Harthy, A.A., Kharaba, A., Al-Jabbary, A., Pinto, R., Sadat, M., Mutairi, H.A., Qasim, E.A., Jose, J., Deeb, A.M., Merson, L., Hayden, F.G., Fowler, R., Aldawood, A.S., Effect of ribavirin and interferon on the outcome of critically ill patients with MERS. Am. J. Respir. Crit. Care Med., 195, 2017, A6067.
8. Arabi, Y.M., Al-Enezi, F., Longuere, K.S., Balkhy, H.H., Al-Sultan, M., Al-Omari, A., Al-Hameed, F.M., Carson, G., Shindo, N., Fowler, R., Feasibility of a randomized controlled trial to assess treatment of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection in Saudi Arabia: a survey of physicians. BMC Anesthesiol., 16, 2016, 36.
9. Arabi, Y.M., Alothman, A., Balkhy, H.H., Al-Dawood, A., AlJohani, S., Al Harbi, S., Kojan, S., Al Jeraisy, M., Deeb, A.M., Assiri, A.M., Al-Hameed, F., AlSaedi, A., Mandourah, Y., Almekhlafi, G.A., Sherbeeni, N.M., Elzein, F.E., Memon, J., Taha, Y., Almotairi, A., Maghrabi, K.A., Qushmaq, I., Al Bshabshe, A., Kharaba, A., Shalhoub, S., Jose, J., Fowler, R.A., Hayden, F.G., Hussein, M.A., the, M.t.g. Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-beta1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials, 19, 2018, 81.
10. Arabi, Y.M., Balkhy, H.H., Hayden, F.G., Bouchama, A., Luke, T., Baillie, J.K., Al-Omari, A., Hajeer, A.H., Senga, M., Denison, M.R., Nguyen-Van-Tam, J.S., Shindo, N., Bermingham, A., Chappell, J.D., Van Kerkhove, M.D., Fowler, R.A., Middle East respiratory syndrome. N. Engl. J. Med. 376 (2017), 584–594.
11. Arabi, Y.M., Mandourah, Y., Al-Hameed, F., Sindi, A.A., Almekhlafi, G.A., Hussein, M.A., Jose, J., Pinto, R., Al-Omari, A., Kharaba, A., Almotairi, A., Al Khatib, K., Alraddadi, B., Shalhoub, S., Abdulmomen, A., Qushmaq, I., Mady, A., Solaiman, O., Al-Aithan, A.M., Al-Raddadi, R., Ragab, A., Balkhy, H.H., Al Harthy, A., Deeb, A.M., Al Mutairi, H., Al-Dawood, A., Merson, L., Hayden, F.G., Fowler, R.A., Saudi Critical Care Trial, G. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am. J. Respir. Crit. Care Med. 197 (2018), 757–767.
12. Baranovich, T., Saito, R., Suzuki, Y., Zaraket, H., Dapat, C., Caperig-Dapat, I., Oguma, T., Shabana, I.I., Saito, T., Suzuki, H., Japanese Influenza Collaborative Study, G. Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008-2009 season. J. Clin. Virol. 47 (2010), 23–28.
13. Beaird, O.E., Freifeld, A., Ison, M.G., Lawrence, S.J., Theodoropoulos, N., Clark, N.M., Razonable, R.R., Alangaden, G., Miller, R., Smith, J., Young, J.A., Hawkinson, D., Pursell, K., Kaul, D.R., Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: a survey of institutions in the Midwestern respiratory virus collaborative. Transpl. Infect. Dis. 18 (2016), 210–215.
14. Becker, M.M., Graham, R.L., Donaldson, E.F., Rockx, B., Sims, A.C., Sheahan, T., Pickles, R.J., Corti, D., Johnston, R.E., Baric, R.S., Denison, M.R., Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 19944–19949.
15. Beigel, J.H., Tebas, P., Elie-Turenne, M.C., Bajwa, E., Bell, T.E., Cairns, C.B., Shoham, S., Deville, J.G., Feucht, E., Feinberg, J., Luke, T., Raviprakash, K., Danko, J., O'Neil, D., Metcalf, J.A., King, K., Burgess, T.H., Aga, E., Lane, H.C., Hughes, M.D., Davey, R.T., Team, I.R.C.S., Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study. Lancet Respir. Med. 5 (2017), 500–511.
16. Beigel, J.H., Voell, J., Kumar, P., Raviprakash, K., Wu, H., Jiao, J.A., Sullivan, E., Luke, T., Davey, R.T. Jr., Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study. Lancet Infect. Dis. 18 (2018), 410–418.
17. Beigi, R.H., Han, K., Venkataramanan, R., Hankins, G.D., Clark, S., Hebert, M.F., Easterling, T., Zajicek, A., Ren, Z., Mattison, D.R., Caritis, S.N., Obstetric-Fetal Pharmacology Research Units, N. Pharmacokinetics of oseltamivir among pregnant and nonpregnant women. Am. J. Obstet. Gynecol. 204 (2011), S84–S88.
18. Belardo, G., Frazia, S.L., Cenciarelli, O., Carta, S., Rossignol, J.-F., Santoro, M.G., Nitazoxanide, a novel potential anti-influenza drug. Acting in Synergism with Neuraminidase Inhibitors, IDSA Poster Abstract Session, October 22, 2011, 2011 (Boston, MA).
19. Blaising, J., Polyak, S.J., Pecheur, E.I., Arbidol as a broad-spectrum antiviral: an update. Antivir. Res. 107 (2014), 84–94.
20. Borghardt, J.M., Kloft, C., Sharma, A., Inhaled therapy in respiratory disease: the complex interplay of pulmonary kinetic processes. Can. Respir. J., 2018, 2018, 2732017.
21. Bright, R.A., Medina, M.J., Xu, X., Perez-Oronoz, G., Wallis, T.R., Davis, X.M., Povinelli, L., Cox, N.J., Klimov, A.I., Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366 (2005), 1175–1181.
22. Byrn, R.A., Jones, S.M., Bennett, H.B., Bral, C., Clark, M.P., Jacobs, M.D., Kwong, A.D., Ledeboer, M.W., Leeman, J.R., McNeil, C.F., Murcko, M.A., Nezami, A., Perola, E., Rijnbrand, R., Saxena, K., Tsai, A.W., Zhou, Y., Charifson, P.S., Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit. Antimicrob. Agents Chemother. 59 (2015), 1569–1582.
23. Carson, G.L., Castle, L., George, M., Horby, P., Longuere, K.S., Merson, L., Murthy, S., O'neill, G., Pardinaz-Solis, R., Webb, S., Short period incidence sTudy of severe acute respiratory infection (SPRINT-SARI) initial data from a global observational study to better describe SARI epidemiology in critically ill patients. Int. J. Infect. Dis., 53, 2016, 101.
24. Centers for Disease, C., Prevention, Update: influenza activity--United States, September 28, 2008-April 4, 2009, and composition of the 2009-10 influenza vaccine. MMWR Morb. Mortal. Wkly. Rep. 58 (2009), 369–374.
25. Chan, J.F., Chan, K.H., Kao, R.Y., To, K.K., Zheng, B.J., Li, C.P., Li, P.T., Dai, J., Mok, F.K., Chen, H., Hayden, F.G., Yuen, K.Y., Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J. Infect. 67 (2013), 606–616.
26. Chan, J.F., Yao, Y., Yeung, M.L., Deng, W., Bao, L., Jia, L., Li, F., Xiao, C., Gao, H., Yu, P., Cai, J.P., Chu, H., Zhou, J., Chen, H., Qin, C., Yuen, K.Y., Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J. Infect. Dis. 212 (2015), 1904–1913.
27. Chevalier, A., Silva, D.A., Rocklin, G.J., Hicks, D.R., Vergara, R., Murapa, P., Bernard, S.M., Zhang, L., Lam, K.H., Yao, G., Bahl, C.D., Miyashita, S.I., Goreshnik, I., Fuller, J.T., Koday, M.T., Jenkins, C.M., Colvin, T., Carter, L., Bohn, A., Bryan, C.M., Fernandez-Velasco, D.A., Stewart, L., Dong, M., Huang, X., Jin, R., Wilson, I.A., Fuller, D.H., Baker, D., Massively parallel de novo protein design for targeted therapeutics. Nature 550 (2017), 74–79.
28. Chu, C.M., Cheng, V.C., Hung, I.F., Wong, M.M., Chan, K.H., Chan, K.S., Kao, R.Y., Poon, L.L., Wong, C.L., Guan, Y., Peiris, J.S., Yuen, K.Y., Group, H.U.S.S., Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 59 (2004), 252–256.
29. Coates, M., Brookes, D., Kim, Y.I., Allen, H., Fordyce, E.A.F., Meals, E.A., Colley, T., Ciana, C.L., Parra, G.F., Sherbukhin, V., Stockwell, J.A., Thomas, J.C., Hunt, S.F., Anderson-Dring, L., Onions, S.T., Cass, L., Murray, P.J., Ito, K., Strong, P., DeVincenzo, J.P., Rapeport, G., Preclinical characterization of PC786, an inhaled small-molecule respiratory syncytial virus L protein polymerase inhibitor. Antimicrob. Agents Chemother., 61, 2017.
30. Cockrell, A.S., Yount, B.L., Scobey, T., Jensen, K., Douglas, M., Beall, A., Tang, X.C., Marasco, W.A., Heise, M.T., Baric, R.S., A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. Nat. Microbiol., 2, 2016, 16226.
31. Croxtall, J.D., Perry, C.M., Lopinavir/Ritonavir: a review of its use in the management of HIV-1 infection. Drugs 70 (2010), 1885–1915.
32. de Jong, M.D., Ison, M.G., Monto, A.S., Metev, H., Clark, C., O'Neil, B., Elder, J., McCullough, A., Collis, P., Sheridan, W.P., Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients. Clin. Infect. Dis. 59 (2014), e172–185.
33. de Wilde, A.H., Jochmans, D., Posthuma, C.C., Zevenhoven-Dobbe, J.C., van Nieuwkoop, S., Bestebroer, T.M., van den Hoogen, B.G., Neyts, J., Snijder, E.J., Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob. Agents Chemother. 58 (2014), 4875–4884.
34. de Wilde, A.H., Raj, V.S., Oudshoorn, D., Bestebroer, T.M., van Nieuwkoop, S., Limpens, R.W., Posthuma, C.C., van der Meer, Y., Barcena, M., Haagmans, B.L., Snijder, E.J., van den Hoogen, B.G., MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-alpha treatment. J. Gen. Virol. 94 (2013), 1749–1760.
35. DeVincenzo, J.P., El Saleeby, C.M., Bush, A.J., Respiratory syncytial virus load predicts disease severity in previously healthy infants. J. Infect. Dis. 191 (2005), 1861–1868.
36. DeVincenzo, J.P., McClure, M.W., Symons, J.A., Fathi, H., Westland, C., Chanda, S., Lambkin-Williams, R., Smith, P., Zhang, Q., Beigelman, L., Blatt, L.M., Fry, J., Activity of oral ALS-008176 in a respiratory syncytial virus challenge study. N. Engl. J. Med. 373 (2015), 2048–2058.
37. DeVincenzo, J.P., Whitley, R.J., Mackman, R.L., Scaglioni-Weinlich, C., Harrison, L., Farrell, E., McBride, S., Lambkin-Williams, R., Jordan, R., Xin, Y., Ramanathan, S., O'Riordan, T., Lewis, S.A., Li, X., Toback, S.L., Lin, S.L., Chien, J.W., Oral GS-5806 activity in a respiratory syncytial virus challenge study. N. Engl. J. Med. 371 (2014), 711–722.
38. DeVincenzo, J.P., Wilkinson, T., Vaishnaw, A., Cehelsky, J., Meyers, R., Nochur, S., Harrison, L., Meeking, P., Mann, A., Moane, E., Oxford, J., Pareek, R., Moore, R., Walsh, E., Studholme, R., Dorsett, P., Alvarez, R., Lambkin-Williams, R., Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am. J. Respir. Crit. Care Med. 182 (2010), 1305–1314.
39. Dias, A., Bouvier, D., Crepin, T., McCarthy, A.A., Hart, D.J., Baudin, F., Cusack, S., Ruigrok, R.W., The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit. Nature 458 (2009), 914–918.
40. Dimmock, N.J., Rainsford, E.W., Scott, P.D., Marriott, A.C., Influenza virus protecting RNA: an effective prophylactic and therapeutic antiviral. J. Virol. 82 (2008), 8570–8578.
41. Dobson, J., Whitley, R.J., Pocock, S., Monto, A.S., Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet 385 (2015), 1729–1737.
42. Dumitrescu, L., Constantinescu, C.S., Tanasescu, R., Recent developments in interferon-based therapies for multiple sclerosis. Expert Opin. Biol. Ther. 18 (2018), 665–680.
43. El Saleeby, C.M., Bush, A.J., Harrison, L.M., Aitken, J.A., Devincenzo, J.P., Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children. J. Infect. Dis. 204 (2011), 996–1002.
44. European Medicines Agency, Agency, E.M., (eds.) Guidelines on the Clinical Evaluation of Medicinal Products Indicated for the Prophylaxis or Treatment of Respiratory Syncytial Virus (RSV) Disease, 2018 EMA/CHMP/257022/2017.
45. Falsey, A.R., Hennessey, P.A., Formica, M.A., Cox, C., Walsh, E.E., Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 352 (2005), 1749–1759.
46. Falsey, A.R., McElhaney, J.E., Beran, J., van Essen, G.A., Duval, X., Esen, M., Galtier, F., Gervais, P., Hwang, S.J., Kremsner, P., Launay, O., Leroux-Roels, G., McNeil, S.A., Nowakowski, A., Richardus, J.H., Ruiz-Palacios, G., St Rose, S., Devaster, J.M., Oostvogels, L., Durviaux, S., Taylor, S., Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illness. J. Infect. Dis. 209 (2014), 1873–1881.
47. Falzarano, D., de Wit, E., Rasmussen, A.L., Feldmann, F., Okumura, A., Scott, D.P., Brining, D., Bushmaker, T., Martellaro, C., Baseler, L., Benecke, A.G., Katze, M.G., Munster, V.J., Feldmann, H., Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat. Med. 19 (2013), 1313–1317.
48. Finberg, R.W., Lanno, R., Anderson, D., Fleischhackl, R., van Duijnhoven, W., Kauffman, R.S., Kosoglou, T., Vingerhoets, J., Leopold, L., Phase 2b study of pimodivir (JNJ-63623872) as monotherapy or in combination with oseltamivir for treatment of acute uncomplicated seasonal influenza A: TOPAZ trial. J. Infect. Dis. 219:7 (2019 Mar 15), 1026–1034.
49. Fleishman, S.J., Whitehead, T.A., Ekiert, D.C., Dreyfus, C., Corn, J.E., Strauch, E.M., Wilson, I.A., Baker, D., Computational design of proteins targeting the conserved stem region of influenza hemagglutinin. Science 332 (2011), 816–821.
50. Fukao, K., Noshi, T., Yamamoto, A., Kitano, M., Ando, Y., Noda, T., Baba, K., Matsumoto, K., Higuchi, N., Ikeda, M., Shishido, T., Naito, A., Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection. J. Antimicrob. Chemother. 74 (2019), 654–662.
51. Furuta, Y., Gowen, B.B., Takahashi, K., Shiraki, K., Smee, D.F., Barnard, D.L., Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antivir. Res. 100 (2013), 446–454.
52. Gaggar, A., Jackson, P.L., Noerager, B.D., O'Reilly, P.J., McQuaid, D.B., Rowe, S.M., Clancy, J.P., Blalock, J.E., A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J. Immunol. 180 (2008), 5662–5669.
53. Gamino-Arroyo, A.E., Guerrero, M.L., McCarthy, S., Ramirez-Venegas, A., Llamosas-Gallardo, B., Galindo-Fraga, A., Moreno-Espinosa, S., Roldan-Aragon, Y., Araujo-Melendez, J., Hunsberger, S., Ibarra-Gonzalez, V., Martinez-Lopez, J., Garcia-Andrade, L.A., Kapushoc, H., Holley, H.P. Jr., Smolskis, M.C., Ruiz-Palacios, G.M., Beigel, J.H., Mexico Emerging Infectious Diseases Clinical Research, N. Efficacy and safety of nitazoxanide in addition to standard of care for the treatment of severe acute respiratory illness. Clin. Infect. Dis., 2019 Feb 7, 10.1093/cid/ciz100 [Epub ahead of print].
54. Global Burden of Disease Collaborators, Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect. Dis. 18 (2018), 1191–1210.
55. Greer, L.G., Leff, R.D., Rogers, V.L., Roberts, S.W., McCracken, G.H. Jr., Wendel, G.D. Jr., Sheffield, J.S., Pharmacokinetics of oseltamivir in breast milk and maternal plasma. Am. J. Obstet. Gynecol. 204 (2011), 524 e521–524.
56. Gubareva, L.V., Besselaar, T.G., Daniels, R.S., Fry, A., Gregory, V., Huang, W., Hurt, A.C., Jorquera, P.A., Lackenby, A., Leang, S.K., Lo, J., Pereyaslov, D., Rebelo-de-Andrade, H., Siqueira, M.M., Takashita, E., Odagiri, T., Wang, D., Zhang, W., Meijer, A., Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016. Antivir. Res. 146 (2017), 12–20.
57. Gubareva, L.V., Mishin, V.P., Patel, M.C., Chesnokov, A., Nguyen, H.T., De La Cruz, J., Spencer, S., Campbell, A.P., Sinner, M., Reid, H., Garten, R., Katz, J.M., Fry, A.M., Barnes, J., Wentworth, D.E., Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons. Euro Surveill., 24, 2019.
58. Gupta, P., Kamath, A.V., Park, S., Chiu, H., Lutman, J., Maia, M., Tan, M.-W., Xu, M., Swem, L., Deng, R., Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A. mAbs 8 (2016), 991–997.
59. Haffizulla, J., Hartman, A., Hoppers, M., Resnick, H., Samudrala, S., Ginocchio, C., Bardin, M., Rossignol, J.F., Group, U.S.N.I.C.S. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial. Lancet Infect. Dis. 14 (2014), 609–618.
60. Hall, C.B., Weinberg, G.A., Iwane, M.K., Blumkin, A.K., Edwards, K.M., Staat, M.A., Auinger, P., Griffin, M.R., Poehling, K.A., Erdman, D., Grijalva, C.G., Zhu, Y., Szilagyi, P., The burden of respiratory syncytial virus infection in young children. N. Engl. J. Med. 360 (2009), 588–598.
61. Hart, B.J., Dyall, J., Postnikova, E., Zhou, H., Kindrachuk, J., Johnson, R.F., Olinger, G.G. Jr., Frieman, M.B., Holbrook, M.R., Jahrling, P.B., Hensley, L., Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J. Gen. Virol. 95 (2014), 571–577.
62. Hayden, F.G., Sugaya, N., Hirotsu, N., Lee, N., de Jong, M.D., Hurt, A.C., Ishida, T., Sekino, H., Yamada, K., Portsmouth, S., Kawaguchi, K., Shishido, T., Arai, M., Tsuchiya, K., Uehara, T., Watanabe, A., Baloxavir Marboxil Investigators, G., Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N. Engl. J. Med. 379 (2018), 913–923.
63. Hershberger, E., Sloan, S., Narayan, K., Hay, C.A., Smith, P., Engler, F., Jeeninga, R., Smits, S., Trevejo, J., Shriver, Z., Oldach, D., Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: results from a randomized, double-blind, phase-2, placebo-controlled study. EBioMedicine 40 (2019 Feb), 574–582.
64. Hui, D.S., Lee, N., Chan, P.K., Beigel, J.H., The role of adjuvant immunomodulatory agents for treatment of severe influenza. Antivir. Res. 150 (2018), 202–216.
65. Hung, I.F., To, K.K., Lee, C.K., Lee, K.L., Chan, K., Yan, W.W., Liu, R., Watt, C.L., Chan, W.M., Lai, K.Y., Koo, C.K., Buckley, T., Chow, F.L., Wong, K.K., Chan, H.S., Ching, C.K., Tang, B.S., Lau, C.C., Li, I.W., Liu, S.H., Chan, K.H., Lin, C.K., Yuen, K.Y., Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin. Infect. Dis. 52 (2011), 447–456.
66. Hung, I.F.N., To, K.K.W., Chan, J.F.W., Cheng, V.C.C., Liu, K.S.H., Tam, A., Chan, T.C., Zhang, A.J., Li, P., Wong, T.L., Zhang, R., Cheung, M.K.S., Leung, W., Lau, J.Y.N., Fok, M., Chen, H., Chan, K.H., Yuen, K.Y., Efficacy of clarithromycin-naproxen-oseltamivir combination in the treatment of patients hospitalized for influenza A(H3N2) infection: an open-label randomized, controlled, phase IIb/III trial. Chest 151 (2017), 1069–1080.
67. Hung, I.F.N., To, K.K.W., Lee, C.K., Lee, K.L., Yan, W.W., Chan, K., Chan, W.M., Ngai, C.W., Law, K.I., Chow, F.L., Liu, R., Lai, K.Y., Lau, C.C.Y., Liu, S.H., Chan, K.H., Lin, C.K., Yuen, K.Y., Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest 144 (2013), 464–473.
68. Ison, M., Options IX. Chicago. Abstract LBP-17, 2016.
69. Ison, M.G., Improving delivery of early treatment to influenza-infected patients. Clin. Infect. Dis. 66 (2017), 1042–1044.
70. Ison, M.G., de Jong, M.D., Gilligan, K.J., Higgs, E.S., Pavia, A.T., Pierson, J., Hayden, F.G., End points for testing influenza antiviral treatments for patients at high risk of severe and life-threatening disease. J. Infect. Dis. 201 (2010), 1654–1662.
71. Ison, M.G., Portsmouth, S., Yoshida, Y., Shishido, T., Hayden, F., Uehara, T., LB16. Phase 3 trial of baloxavir marboxil in high-risk influenza patients (CAPSTONE-2 study). Open Forum Infect. Dis. 5 (2018), S764–S765.
72. Jones, J.C., Kumar, G., Barman, S., Najera, I., White, S.W., Webby, R.J., Govorkova, E.A., Identification of the I38T PA substitution as a resistance marker for next-generation influenza virus endonuclease inhibitors. mBio, 9, 2018.
73. Jones, J.C., Marathe, B.M., Lerner, C., Kreis, L., Gasser, R., Pascua, P.N., Najera, I., Govorkova, E.A., A novel endonuclease inhibitor exhibits broad-spectrum anti-influenza virus activity in vitro. Antimicrob. Agents Chemother. 60 (2016), 5504–5514.
74. Ju, H., Zhang, J., Huang, B., Kang, D., Huang, B., Liu, X., Zhan, P., Inhibitors of influenza virus polymerase acidic (PA) endonuclease: contemporary developments and perspectives. J. Med. Chem. 60 (2017), 3533–3551.
75. Kadam, R.U., Wilson, I.A., Structural basis of influenza virus fusion inhibition by the antiviral drug arbidol. Proc. Natl. Acad. Sci. U. S. A. 114 (2017), 206–214.
76. Kawai, N., Ikematsu, H., Hirotsu, N., Maeda, T., Kawashima, T., Tanaka, O., Yamauchi, S., Kawamura, K., Matsuura, S., Nishimura, M., Iwaki, N., Kashiwagi, S., Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons. Clin. Infect. Dis. 49 (2009), 1828–1835.
77. Kim, Y.I., DeVincenzo, J.P., Jones, B.G., Rudraraju, R., Harrison, L., Meyers, R., Cehelsky, J., Alvarez, R., Hurwitz, J.L., Respiratory syncytial virus human experimental infection model: provenance, production, and sequence of low-passaged memphis-37 challenge virus. PLoS One, 9, 2014, e113100.
78. Kim, Y.I., Pareek, R., Murphy, R., Harrison, L., Farrell, E., Cook, R., DeVincenzo, J., The antiviral effects of RSV fusion inhibitor, MDT-637, on clinical isolates, vs its achievable concentrations in the human respiratory tract and comparison to ribavirin. Influenza Other Respir Viruses 11 (2017), 525–530.
79. King, J., IDWeek 2016. New Orleans. Abstract 638, 2016.
80. Laursen, N.S., Friesen, R.H.E., Zhu, X., Jongeneelen, M., Blokland, S., Vermond, J., van Eijgen, A., Tang, C., van Diepen, H., Obmolova, G., van der Neut Kolfschoten, M., Zuijdgeest, D., Straetemans, R., Hoffman, R.M.B., Nieusma, T., Pallesen, J., Turner, H.L., Bernard, S.M., Ward, A.B., Luo, J., Poon, L.L.M., Tretiakova, A.P., Wilson, J.M., Limberis, M.P., Vogels, R., Brandenburg, B., Kolkman, J.A., Wilson, I.A., Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin. Science 362 (2018), 598–602.
81. Lee, N., Wong, C.K., Chan, M.C.W., Yeung, E.S.L., Tam, W.W.S., Tsang, O.T.Y., Choi, K.W., Chan, P.K.S., Kwok, A., Lui, G.C.Y., Leung, W.S., Yung, I.M.H., Wong, R.Y.K., Cheung, C.S.K., Hui, D.S.C., Anti-inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: a randomized controlled trial. Antivir. Res. 144 (2017), 48–56.
82. Leneva, I.A., Burtseva, E.I., Yatsyshina, S.B., Fedyakina, I.T., Kirillova, E.S., Selkova, E.P., Osipova, E., Maleev, V.V., Virus susceptibility and clinical effectiveness of anti-influenza drugs during the 2010-2011 influenza season in Russia. Int. J. Infect. Dis. 43 (2016), 77–84.
83. Li, S.F., Gong, M.J., Zhao, F.R., Shao, J.J., Xie, Y.L., Zhang, Y.G., Chang, H.Y., Type I interferons: distinct biological activities and current applications for viral infection. Cell. Physiol. Biochem. 51 (2018), 2377–2396.
84. Lina, B., Boucher, C., Osterhaus, A., Monto, A.S., Schutten, M., Whitley, R.J., Nguyen-Van-Tam, J.S., Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the influenza resistance information study. Influenza Other Respir Viruses 12 (2018), 267–278.
85. Lipworth, B.J., Pharmacokinetics of inhaled drugs. Br. J. Clin. Pharmacol. 42 (1996), 697–705.
86. Lo, M.K., Jordan, R., Arvey, A., Sudhamsu, J., Shrivastava-Ranjan, P., Hotard, A.L., Flint, M., McMullan, L.K., Siegel, D., Clarke, M.O., Mackman, R.L., Hui, H.C., Perron, M., Ray, A.S., Cihlar, T., Nichol, S.T., Spiropoulou, C.F., GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Sci. Rep., 7, 2017, 43395.
87. Luke, T., Wu, H., Zhao, J., Channappanavar, R., Coleman, C.M., Jiao, J.A., Matsushita, H., Liu, Y., Postnikova, E.N., Ork, B.L., Glenn, G., Flyer, D., Defang, G., Raviprakash, K., Kochel, T., Wang, J., Nie, W., Smith, G., Hensley, L.E., Olinger, G.G., Kuhn, J.H., Holbrook, M.R., Johnson, R.F., Perlman, S., Sullivan, E., Frieman, M.B., Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo. Sci. Transl. Med., 8, 2016 326ra321.
88. Luke, T.C., Kilbane, E.M., Jackson, J.L., Hoffman, S.L., Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?. Ann. Intern. Med. 145 (2006), 599–609.
89. Martinon-Torres, F., Rusch, S., Huntjens, D., Remmerie, B., Vingerhoets, J., McFadyen, K., Stevens, M., Antiviral effects, pharmacokinetics and safety of the respiratory syncytial virus fusion protein inhibitor, JNJ-53718678. RSV-infected Infants with Bronchiolitis, in the Phase 1b Study 53718678RSV1005, 2018, IDWeek 2018, San Francisco, CA.
90. Marty, F.M., Vidal-Puigserver, J., Clark, C., Gupta, S.K., Merino, E., Garot, D., Chapman, M.J., Jacobs, F., Rodriguez-Noriega, E., Husa, P., Shortino, D., Watson, H.A., Yates, P.J., Peppercorn, A.F., Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial. Lancet Respir. Med. 5 (2017), 135–146.
91. McBride, J.M., Lim, J.J., Burgess, T., Deng, R., Derby, M.A., Maia, M., Horn, P., Siddiqui, O., Sheinson, D., Chen-Harris, H., Newton, E.M., Fillos, D., Nazzal, D., Rosenberger, C.M., Ohlson, M.B., Lambkin-Williams, R., Fathi, H., Harris, J.M., Tavel, J.A., Phase 2 randomized trial of the safety and efficacy of MHAA4549A, a broadly neutralizing monoclonal antibody, in a human influenza a virus challenge model. Antimicrob. Agents Chemother., 61, 2017, 17.
92. McKimm-Breschkin, J.L., Jiang, S., Hui, D.S., Beigel, J.H., Govorkova, E.A., Lee, N., Prevention and treatment of respiratory viral infections: presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference. Antivir. Res. 149 (2018), 118–142.
93. Memoli, M.J., Athota, R., Reed, S., Czajkowski, L., Bristol, T., Proudfoot, K., Hagey, R., Voell, J., Fiorentino, C., Ademposi, A., Shoham, S., Taubenberger, J.K., The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts. Clin. Infect. Dis. 58 (2014), 214–224.
94. Menachery, V.D., Yount, B.L. Jr., Debbink, K., Agnihothram, S., Gralinski, L.E., Plante, J.A., Graham, R.L., Scobey, T., Ge, X.Y., Donaldson, E.F., Randell, S.H., Lanzavecchia, A., Marasco, W.A., Shi, Z.L., Baric, R.S., A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat. Med. 21 (2015), 1508–1513.
95. Menachery, V.D., Yount, B.L. Jr., Sims, A.C., Debbink, K., Agnihothram, S.S., Gralinski, L.E., Graham, R.L., Scobey, T., Plante, J.A., Royal, S.R., Swanstrom, J., Sheahan, T.P., Pickles, R.J., Corti, D., Randell, S.H., Lanzavecchia, A., Marasco, W.A., Baric, R.S., SARS-like WIV1-CoV poised for human emergence. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), 3048–3053.
96. Nicholson, E.G., Munoz, F.M., A review of therapeutics in clinical development for respiratory syncytial virus and influenza in children. Clin. Ther. 40 (2018), 1268–1281.
97. Noshi, T., Kitano, M., Taniguchi, K., Yamamoto, A., Omoto, S., Baba, K., Hashimoto, T., Ishida, K., Kushima, Y., Hattori, K., Kawai, M., Yoshida, R., Kobayashi, M., Yoshinaga, T., Sato, A., Okamatsu, M., Sakoda, Y., Kida, H., Shishido, T., Naito, A., In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antivir. Res. 160 (2018), 109–117.
98. Olsson, B., Bondesson, E., Borgström, L., Edsbäcker, S., Eirefelt, S., Ekelund, K., Pulmonary drug metabolism, clearance, and absorption. Controlled Pulmonary Drug Delivery, 2011, 21–50.
99. Omoto, S., Speranzini, V., Hashimoto, T., Noshi, T., Yamaguchi, H., Kawai, M., Kawaguchi, K., Uehara, T., Shishido, T., Naito, A., Cusack, S., Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci. Rep., 8, 2018, 9633.
100. Omrani, A.S., Saad, M.M., Baig, K., Bahloul, A., Abdul-Matin, M., Alaidaroos, A.Y., Almakhlafi, G.A., Albarrak, M.M., Memish, Z.A., Albarrak, A.M., Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect. Dis. 14 (2014), 1090–1095.
101. Pascua, P.N.Q., Mostafa, H.H., Marathe, B.M., Vogel, P., Russell, C.J., Webby, R.J., Govorkova, E.A., Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection. Sci. Rep., 7, 2017, 7345.
102. Patel, M.C., Shirey, K.A., Boukhvalova, M.S., Vogel, S.N., Blanco, J.C.G., Serum high-mobility-group box 1 as a biomarker and a therapeutic target during respiratory virus infections. mBio, 9, 2018.
103. Perkins, S.M., Webb, D.L., Torrance, S.A., El Saleeby, C., Harrison, L.M., Aitken, J.A., Patel, A., DeVincenzo, J.P., Comparison of a real-time reverse transcriptase PCR assay and a culture technique for quantitative assessment of viral load in children naturally infected with respiratory syncytial virus. J. Clin. Microbiol. 43 (2005), 2356–2362.
104. Perrin-Cocon, L., Aublin-Gex, A., Sestito, S.E., Shirey, K.A., Patel, M.C., Andre, P., Blanco, J.C., Vogel, S.N., Peri, F., Lotteau, V., TLR4 antagonist FP7 inhibits LPS-induced cytokine production and glycolytic reprogramming in dendritic cells, and protects mice from lethal influenza infection. Sci. Rep., 7, 2017, 40791.
105. Perron, M., Stray, K., Kinkade, A., Theodore, D., Lee, G., Eisenberg, E., Sangi, M., Gilbert, B.E., Jordan, R., Piedra, P.A., Toms, G.L., Mackman, R., Cihlar, T., GS-5806 inhibits a broad range of respiratory syncytial virus clinical isolates by blocking the virus-cell fusion process. Antimicrob. Agents Chemother. 60 (2015), 1264–1273.
106. Perry, M.E., Taylor, G.P., Sabin, C.A., Conway, K., Flanagan, S., Dwyer, E., Stevenson, J., Mulka, L., McKendry, A., Williams, E., Barbour, A., Dermont, S., Roedling, S., Shah, R., Anderson, J., Rodgers, M., Wood, C., Sarner, L., Hay, P., Hawkins, D., deRuiter, A., Lopinavir and atazanavir in pregnancy: comparable infant outcomes, virological efficacies and preterm delivery rates. HIV Med. 17 (2016), 28–35.
107. Peterson, R.L., Vock, D.M., Powers, J.H., Emery, S., Cruz, E.F., Hunsberger, S., Jain, M.K., Pett, S., Neaton, J.D., Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization. Clin. Trials 14 (2017), 264–276.
108. Piacentini, S., La Frazia, S., Riccio, A., Pedersen, J.Z., Topai, A., Nicolotti, O., Rossignol, J.F., Santoro, M.G., Nitazoxanide inhibits paramyxovirus replication by targeting the Fusion protein folding: role of glycoprotein-specific thiol oxidoreductase ERp57. Sci. Rep., 8, 2018, 10425.
109. Piao, W., Shirey, K.A., Ru, L.W., Lai, W., Szmacinski, H., Snyder, G.A., Sundberg, E.J., Lakowicz, J.R., Vogel, S.N., Toshchakov, V.Y., A decoy peptide that disrupts TIRAP recruitment to TLRs is protective in a murine model of influenza. Cell Rep. 11 (2015), 1941–1952.
110. Pizzorno, A., Terrier, O., Nicolas de Lamballerie, C., Julien, T., Padey, B., Traversier, A., Roche, M., Hamelin, M.E., Rheaume, C., Croze, S., Escuret, V., Poissy, J., Lina, B., Legras-Lachuer, C., Textoris, J., Boivin, G., Rosa-Calatrava, M., Repurposing of drugs as novel influenza inhibitors from clinical gene expression infection signatures. Front. Immunol., 10, 2019, 60.
111. Powers, J.H. 3rd, Bacci, E.D., Guerrero, M.L., Leidy, N.K., Stringer, S., Kim, K., Memoli, M.J., Han, A., Fairchok, M.P., Chen, W.J., Arnold, J.C., Danaher, P.J., Lalani, T., Ridore, M., Burgess, T.H., Millar, E.V., Hernandez, A., Rodriguez-Zulueta, P., Smolskis, M.C., Ortega-Gallegos, H., Pett, S., Fischer, W., Gillor, D., Macias, L.M., DuVal, A., Rothman, R., Dugas, A., Ruiz-Palacios, G.M., Reliability, validity, and responsiveness of InFLUenza patient-reported outcome (FLU-PRO(c)) scores in influenza-positive patients. Value Health 21 (2018), 210–218.
112. Rockx, B., Corti, D., Donaldson, E., Sheahan, T., Stadler, K., Lanzavecchia, A., Baric, R., Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge. J. Virol. 82 (2008), 3220–3235.
113. Rockx, B., Sheahan, T., Donaldson, E., Harkema, J., Sims, A., Heise, M., Pickles, R., Cameron, M., Kelvin, D., Baric, R., Synthetic reconstruction of zoonotic and early human severe acute respiratory syndrome coronavirus isolates that produce fatal disease in aged mice. J. Virol. 81 (2007), 7410–7423.
114. Rodrigo, C., Leonardi-Bee, J., Nguyen-Van-Tam, J., Lim, W.S., Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst. Rev., 3, 2016, CD010406.
115. Rojas-Quintero, J., Wang, X., Tipper, J., Burkett, P.R., Zuniga, J., Ashtekar, A.R., Polverino, F., Rout, A., Yambayev, I., Hernandez, C., Jimenez, L., Ramirez, G., Harrod, K.S., Owen, C.A., Matrix metalloproteinase-9 deficiency protects mice from severe influenza A viral infection. JCI Insight, 3, 2018.
116. Rossignol, J.F., Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antivir. Res. 110 (2014), 94–103.
117. Royal College of Physicians, O.M., NEWS2 National Early Warning Score. 2018.
118. Shah, P., Grein, J., Vakil, N., Hirai-Yang, A., Murthy, R., 1062: compassionate use of intravenous (IV) zanamivir during the 2013-2014 influenza season: case series of three patients. Open Forum Infect. Dis., 1, 2014 S311-S311.
119. Shakya, A., Bhat, H.R., Ghosh, S.K., Update on nitazoxanide: a multifunctional chemotherapeutic agent. Curr. Drug Discov. Technol. 15 (2018), 201–213.
120. Shalhoub, S., Al-Hameed, F., Mandourah, Y., Balkhy, H.H., Al-Omari, A., Al Mekhlafi, G.A., Kharaba, A., Alraddadi, B., Almotairi, A., Al Khatib, K., Abdulmomen, A., Qushmaq, I., Mady, A., Solaiman, O., Al-Aithan, A.M., Al-Raddadi, R., Ragab, A., Al Harthy, A., Al Qasim, E., Jose, J., Al-Ghamdi, G., Merson, L., Fowler, R., Hayden, F.G., Arabi, Y.M., Critically ill healthcare workers with the middle east respiratory syndrome (MERS): a multicenter study. PLoS One, 13, 2018, e0206831.
121. Sheahan, T., Rockx, B., Donaldson, E., Corti, D., Baric, R., Pathways of cross-species transmission of synthetically reconstructed zoonotic severe acute respiratory syndrome coronavirus. J. Virol. 82 (2008), 8721–8732.
122. Sheahan, T., Rockx, B., Donaldson, E., Sims, A., Pickles, R., Corti, D., Baric, R., Mechanisms of zoonotic severe acute respiratory syndrome coronavirus host range expansion in human airway epithelium. J. Virol. 82 (2008), 2274–2285.
123. Sheahan, T.P., Sims, A.C., Graham, R.L., Menachery, V.D., Gralinski, L.E., Case, J.B., Leist, S.R., Pyrc, K., Feng, J.Y., Trantcheva, I., Bannister, R., Park, Y., Babusis, D., Clarke, M.O., Mackman, R.L., Spahn, J.E., Palmiotti, C.A., Siegel, D., Ray, A.S., Cihlar, T., Jordan, R., Denison, M.R., Baric, R.S., Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci. Transl. Med., 9, 2017.
124. Shi, T., McAllister, D.A., O'Brien, K.L., Simoes, E.A.F., Madhi, S.A., Gessner, B.D., Polack, F.P., Balsells, E., Acacio, S., Aguayo, C., Alassani, I., Ali, A., Antonio, M., Awasthi, S., Awori, J.O., Azziz-Baumgartner, E., Baggett, H.C., Baillie, V.L., Balmaseda, A., Barahona, A., Basnet, S., Bassat, Q., Basualdo, W., Bigogo, G., Bont, L., Breiman, R.F., Brooks, W.A., Broor, S., Bruce, N., Bruden, D., Buchy, P., Campbell, S., Carosone-Link, P., Chadha, M., Chipeta, J., Chou, M., Clara, W., Cohen, C., de Cuellar, E., Dang, D.A., Dash-Yandag, B., Deloria-Knoll, M., Dherani, M., Eap, T., Ebruke, B.E., Echavarria, M., de Freitas Lazaro Emediato, C.C., Fasce, R.A., Feikin, D.R., Feng, L., Gentile, A., Gordon, A., Goswami, D., Goyet, S., Groome, M., Halasa, N., Hirve, S., Homaira, N., Howie, S.R.C., Jara, J., Jroundi, I., Kartasasmita, C.B., Khuri-Bulos, N., Kotloff, K.L., Krishnan, A., Libster, R., Lopez, O., Lucero, M.G., Lucion, F., Lupisan, S.P., Marcone, D.N., McCracken, J.P., Mejia, M., Moisi, J.C., Montgomery, J.M., Moore, D.P., Moraleda, C., Moyes, J., Munywoki, P., Mutyara, K., Nicol, M.P., Nokes, D.J., Nymadawa, P., da Costa Oliveira, M.T., Oshitani, H., Pandey, N., Paranhos-Baccala, G., Phillips, L.N., Picot, V.S., Rahman, M., Rakoto-Andrianarivelo, M., Rasmussen, Z.A., Rath, B.A., Robinson, A., Romero, C., Russomando, G., Salimi, V., Sawatwong, P., Scheltema, N., Schweiger, B., Scott, J.A.G., Seidenberg, P., Shen, K., Singleton, R., Sotomayor, V., Strand, T.A., Sutanto, A., Sylla, M., Tapia, M.D., Thamthitiwat, S., Thomas, E.D., Tokarz, R., Turner, C., Venter, M., Waicharoen, S., Wang, J., Watthanaworawit, W., Yoshida, L.M., Yu, H., Zar, H.J., Campbell, H., Nair, H., Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet 390 (2017), 946–958.
125. Shirey, K.A., Lai, W., Scott, A.J., Lipsky, M., Mistry, P., Pletneva, L.M., Karp, C.L., McAlees, J., Gioannini, T.L., Weiss, J., Chen, W.H., Ernst, R.K., Rossignol, D.P., Gusovsky, F., Blanco, J.C., Vogel, S.N., The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature 497 (2013), 498–502.
126. Siegel, D., Hui, H.C., Doerffler, E., Clarke, M.O., Chun, K., Zhang, L., Neville, S., Carra, E., Lew, W., Ross, B., Wang, Q., Wolfe, L., Jordan, R., Soloveva, V., Knox, J., Perry, J., Perron, M., Stray, K.M., Barauskas, O., Feng, J.Y., Xu, Y., Lee, G., Rheingold, A.L., Ray, A.S., Bannister, R., Strickley, R., Swaminathan, S., Lee, W.A., Bavari, S., Cihlar, T., Lo, M.K., Warren, T.K., Mackman, R.L., Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses. J. Med. Chem. 60 (2017), 1648–1661.
127. Stachulski, A.V., Swift, K., Cooper, M., Reynolds, S., Norton, D., Slonecker, S.D., Rossignol, J.F., Synthesis and pre-clinical studies of new amino-acid ester thiazolide prodrugs. Eur. J. Med. Chem. 126 (2017), 154–159.
128. Stevaert, A., Dallocchio, R., Dessi, A., Pala, N., Rogolino, D., Sechi, M., Naesens, L., Mutational analysis of the binding pockets of the diketo acid inhibitor L-742,001 in the influenza virus PA endonuclease. J. Virol. 87 (2013), 10524–10538.
129. Stevens, M., Rusch, S., DeVincenzo, J., Kim, Y.I., Harrison, L., Meals, E.A., Boyers, A., Fok-Seang, J., Huntjens, D., Lounis, N., Mari, N.K., Remmerie, B., Roymans, D., Koul, A., Verloes, R., Antiviral activity of oral JNJ-53718678 in healthy adult volunteers challenged with respiratory syncytial virus: a placebo-controlled study. J. Infect. Dis. 218 (2018), 748–756.
130. Takashita, E., Morita, H., Ogawa, R., Nakamura, K., Fujisaki, S., Shirakura, M., Kuwahara, T., Kishida, N., Watanabe, S., Odagiri, T., Susceptibility of influenza viruses to the novel cap-dependent endonuclease inhibitor baloxavir marboxil. Front. Microbiol., 9, 2018, 3026.
131. Temple, R.J., A Regulatory Authority's Opinion about Surrogate Endpoints. 1995, J. Wiley, New York.
132. Tharakaraman, K., Subramanian, V., Viswanathan, K., Sloan, S., Yen, H.L., Barnard, D.L., Leung, Y.H., Szretter, K.J., Koch, T.J., Delaney, J.C., Babcock, G.J., Wogan, G.N., Sasisekharan, R., Shriver, Z., A broadly neutralizing human monoclonal antibody is effective against H7N9. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 10890–10895.
133. Trevejo, J.M., Asmal, M., Vingerhoets, J., Polo, R., Robertson, S., Jiang, Y., Kieffer, T.L., Leopold, L., Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study. Antivir. Ther. 23 (2018), 335–344.
134. U.S. Food & Drug Administration, Guidance for Industry - Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2009.
135. U.S. Food & Drug Administration, Guidance for Industry - Influenza: Developing Drugs for Treatment And/or Prophylaxis. 2011.
136. U.S. Food & Drug Administration, Guidance for Industry - Immunogenicity Assessment for Therapeutic Protein Products. 2014.
137. U.S. Food & Drug Administration, Respiratory Syncytial Virus Infection: Developing Antiviral Drugs for Prophylaxis and Treatment. 2017, Guidance for Industry.
138. U.S. Food & Drug Administration. Critical Path Innovation Meetings (CPIM). 2018.
139. Wang, C.H., Chung, F.T., Lin, S.M., Huang, S.Y., Chou, C.L., Lee, K.Y., Lin, T.Y., Kuo, H.P., Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe H1N1 pneumonia and acute respiratory failure. Crit. Care Med. 42 (2014), 313–321.
140. Warren, T.K., Jordan, R., Lo, M.K., Ray, A.S., Mackman, R.L., Soloveva, V., Siegel, D., Perron, M., Bannister, R., Hui, H.C., Larson, N., Strickley, R., Wells, J., Stuthman, K.S., Van Tongeren, S.A., Garza, N.L., Donnelly, G., Shurtleff, A.C., Retterer, C.J., Gharaibeh, D., Zamani, R., Kenny, T., Eaton, B.P., Grimes, E., Welch, L.S., Gomba, L., Wilhelmsen, C.L., Nichols, D.K., Nuss, J.E., Nagle, E.R., Kugelman, J.R., Palacios, G., Doerffler, E., Neville, S., Carra, E., Clarke, M.O., Zhang, L., Lew, W., Ross, B., Wang, Q., Chun, K., Wolfe, L., Babusis, D., Park, Y., Stray, K.M., Trancheva, I., Feng, J.Y., Barauskas, O., Xu, Y., Wong, P., Braun, M.R., Flint, M., McMullan, L.K., Chen, S.S., Fearns, R., Swaminathan, S., Mayers, D.L., Spiropoulou, C.F., Lee, W.A., Nichol, S.T., Cihlar, T., Bavari, S., Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531 (2016), 381–385.
141. Wetherall, N.T., Trivedi, T., Zeller, J., Hodges-Savola, C., McKimm-Breschkin, J.L., Zambon, M., Hayden, F.G., Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J. Clin. Microbiol. 41 (2003), 742–750.
142. Xofluza, Highlights of Prescribing Information. 2018.
143. Yang, S.G., Cao, B., Liang, L.R., Li, X.L., Xiao, Y.H., Cao, Z.X., Jia, H.Y., Yu, H.J., Xu, Z., Gu, L., Yang, Y.D., Chen, Y., Du, W.B., Yan, X.X., Liang, Z.A., Zhang, W., Zhang, C.L., Chen, W., Guo, C.P., Jiang, X.L., Yang, M., Deng, G.M., Yu, K.J., Hu, K., Zou, Q., Li, L.J., Wang, C., National Influenza, A.P.C.I.G.o.C. Antiviral therapy and outcomes of patients with pneumonia caused by influenza A pandemic (H1N1) virus. PLoS One, 7, 2012, e29652.
144. Yoon, J.J., Toots, M., Lee, S., Lee, M.E., Ludeke, B., Luczo, J.M., Ganti, K., Cox, R.M., Sticher, Z.M., Edpuganti, V., Mitchell, D.G., Lockwood, M.A., Kolykhalov, A.A., Greninger, A.L., Moore, M.L., Painter, G.R., Lowen, A.C., Tompkins, S.M., Fearns, R., Natchus, M.G., Plemper, R.K., Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses. Antimicrob. Agents Chemother., 62, 2018.
145. Zeng, L.Y., Yang, J., Liu, S., Investigational hemagglutinin-targeted influenza virus inhibitors. Expert Opin. Investig. Drugs 26 (2017), 63–73.